Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
Completed · Phase 1
Conditions studied: Prostate Cancer
In brief
The goal of this clinical research study is to find the highest safe dose of docetaxel in combination with Gleevec (imatinib mesylate) that can be given to men with advanced androgen-independent metastatic prostate cancer that involves bone. Docetaxel is a commercial chemotherapy which interferes with the cancer cell ability to divide and grow.
Key facts
- Study ID
- NCT00038194
- Run by
- M.D. Anderson Cancer Center
- People needed
- 28
- Starts
- 2001-10-01
- Expected to finish
- 2005-09-01
- Last updated by the study team
- 2018-10-31
Who can join
Age: any. Sex: male. Healthy volunteers: not accepted.
Where it is running
- U.T. M.D. Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.